

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT

**INCLUSION OF OT-1001 IN THE PRIORITY REVIEW AND APPROVAL
PROCESS OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION**

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that OT-1001 (ZERVIAE), a potent and highly selective histamine-1 receptor antagonist with anti-allergic properties, has been included in the priority review and approval process of National Medical Products Administration of the People’s Republic of China (“**NMPA**”) recently.

OT-1001 (ZERVIAE) was developed by Nicox Ophthalmics, Inc. (“**Nicox**”). The Group obtained an exclusive license from Nicox to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell (or otherwise commercialize) OT-1001 (ZERVIAE) in the Greater China region in March 2019, and extended the exclusive rights to 11 countries in Southeast Asia in March 2020. OT-1001 is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC[®], and is currently commercialized in the United States for ocular itching associated with allergic conjunctivitis. In April 2023, the new drug application for OT-1001 (ZERVIAE) was accepted by NMPA.

The priority review and approval process of NMPA is designed to expedite the approval of drugs that address unmet medical needs or have the potential to offer significant improvements over existing treatment options. The inclusion of OT-1001 (ZERVIAE) in the priority review and approval process of NMPA will accelerate the review and approval process of its new drug application, which is an important step towards commercialization of OT-1001 (ZERVIAE).

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-1001 (ZERVIAE) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumention Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, April 26, 2023

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.